The combined use of capreomycin and ethambutol in re-treatment of pulmonary tuberculosis.
D000328:Adult; D000900:Anti-Bacterial Agents / Q000009:adverse effects / Q000627:therapeutic use*; D000995:Antitubercular Agents / Q000009:adverse effects / Q000627:therapeutic use*; D004352:Drug Resistance, Microbial; D004977:Ethambutol / Q000009:adverse effects / Q000627:therapeutic use*; D005260:Female; D006311:Hearing Disorders / Q000139:chemically induced; D006801:Humans; D007564:Japan; D008297:Male; D008875:Middle Aged; D013302:Streptomyces; D014397:Tuberculosis, Pulmonary / Q000188:drug therapy*; D014786:Vision Disorders / Q000139:chemically induced
D000900:Anti-Bacterial Agents; D000995:Antitubercular Agents; D004977:Ethambutol